Boehringer Ingelheim and Twist Bioscience have entered into a research collaboration that covers multiple antibody research programs.
Twist Bioscience Corporation, a Californian company enabling progress through its offering of high-quality synthetic DNA using its silicon platform, announced a broad-based research collaboration with pharma giant Boehringer Ingelheim International.
Boehringer Ingelheim will use Twist’s proprietary antibody libraries to discover therapeutic antibodies
Under the partnership, Boehringer Ingelheim will use Twist’s proprietary antibody libraries to discover therapeutic antibodies against multiple targets.
Clive R. Wood, Ph.D., Senior Corporate Vice President and Global Head of Discovery Research at Boehringer Ingelheim said:
“Boehringer Ingelheim believes Twist’s ability to generate potent, diverse therapeutic antibodies by mining its comprehensive libraries, combined with our extensive capabilities and experience in drug discovery and development, will enable us to deliver breakthrough opportunities to patients. We look forward to working with Twist on molecular targets in a broad range of disease areas.”
Under the T&C’s of the agreement, Twist Biopharma, a division of Twist, will utilize its “Library of Libraries,” a panel of synthetic antibody phage display libraries derived only from sequences that exist in the human body, to identify potential therapeutic antibody candidates. Twist and Boehringer Ingelheim will collaborate to validate and optimize any resulting new antibody candidates, which could be researched against a variety of therapeutic areas. Boehringer Ingelheim will keep the exclusive global rights to develop and commercialize any of the therapeutic antibodies discovered as part of the partnership.
Twist has the potential to earn up to $710 million in success-based milestone payments
Twist will receive an upfront payment for each program entry. In addition, Twist has the potential to earn up to a total of $710 million in success-based clinical, regulatory and commercial milestone payments for the multiple target discovery programs.
Emily M. Leproust, Ph.D., CEO and co-founder of Twist stated:
“This discovery collaboration with Boehringer Ingelheim covering numerous targets truly illustrates the power of our antibody libraries. We have the ability to generate precise antibodies to a diverse range of targets, which together with Boehringer Ingelheim’s strength in drug development capabilities, could mean multiple new more personalized treatments in the future for patients.”
About Twist Biopharma
By leveraging our unique ability to manufacture DNA at scale, we can construct proprietary antibody libraries precisely designed to match sequences that occur in the human body. This library of libraries gives Twist’s partners an integral and unbiased resource for antibody therapeutic discovery and optimization. This precise and rational approach to library fabrication combined with sophisticated bioinformatics and software expertise expedites antibody discovery by decreasing risk, increasing speed, and reducing the failure rate for antibody therapeutic development.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery.